Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Distinct Pattern of Genomic Changes Associated with Hypoplastic Compared to Hyper/Normoblastic Myelodysplastic Syndromes (MDS)

Aziz Nazha, MD, David J. Seastone, DO, PhD, Tomas Radivoyevitch, PhD, Brittney Dienes, Bartlomiej Przychodzen, Sean Hobson, MA, Sudipto Mukherjee, MD MPH, Hetty E. Carraway, MD, Jennifer S Carew, PhD, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Hideki Makishima, MD PhD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2014) 124 (21): 4603.

https://doi.org/10.1182/blood.V124.21.4603.4603

Published: 2014

Journal Articles

Molecular Predictors of Response in Patients with Myeloid Neoplasms Treated with Lenalidomide

Chantana Polprasert, MD, Tomas Radivoyevitch, PhD, Naoko Hosono, MD PhD, Hideki Makishima, MD PhD, Bartlomiej P Przychodzen, Brittney Dienes, Kathy McGraw, Sudipto Mukherjee, MD MPH, Hetty E. Carraway, MD, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Jaroslaw P. Maciejewski, MD PhD

Blood (2014) 124 (21): 4665.

https://doi.org/10.1182/blood.V124.21.4665.4665

Published: 2014

Journal Articles

Differences in Genomic Patterns and Clinical Outcomes Between African-American and White Patients with Myelodysplastic Syndromes (MDS)

Aziz Nazha, MD, Tomas Radivoyevitch, PhD, David J. Seastone, DO, PhD, Brittney Dienes, Bartlomiej P Przychodzen, Jennifer S. Carew, PhD, Sudipto Mukherjee, MD MPH, Hetty E. Carraway, MD, Anjali S. Advani, MD, Matt E. Kalaycio, MD, Sean Hobson, MA, Gina Rupp, Kristin Colaluca, RN, Aaron T. Gerds, MD MS, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2014) 124 (21): 3274.

https://doi.org/10.1182/blood.V124.21.3274.3274

Published: 2014

Journal Articles

Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia

Valeria Visconte, PhD, Ali Tabarroki, MD, Christopher Gerace, Karam Al-Issa, MD, Eric D. Hsi, MD, Heesun J. Rogers, MD PhD, Mikkael A. Sekeres, MD MS, Bernard J. Silver, MD, Alan E. Lichtin, MD, Sudipto Mukherjee, MD MPH, Ramon V. Tiu, MD

Blood (2014) 124 (21): 5597.

https://doi.org/10.1182/blood.V124.21.5597.5597

Published: 2014

Journal Articles

Estimating Therapy-Related Myeloid Neoplasm Risks in the US

Tomas Radivoyevitch, PhD, Rainer K. Sachs, PhD, Robert Peter Gale, MD PhD DSc, FACP, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Matt Kalaycio, MD, Sudipto Mukherjee, MD MPH

Blood (2014) 124 (21): 2617.

https://doi.org/10.1182/blood.V124.21.2617.2617

Published: 2014

Journal Articles

Time to Complete Remission As a Function of Kinetics of White Blood Cell Elimination and Recovery in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy

Umera Thebo, MD, Tomas Radivoyevitch, PhD, Surbhi Sidana, MD, Cassandra Fincher, Amanda L. Maggiotto, BS, CCRP, Yogen Saunthararajah, MD, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Hetty E. Carraway, MD MBA, Betty K. Hamilton, MD, Matt E. Kalaycio, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD MPH

Blood (2014) 124 (21): 5266.

https://doi.org/10.1182/blood.V124.21.5266.5266

Published: 2014

Journal Articles

A Prognostic Scoring System for Newly Diagnosed Adult Acute Lymphocytic Leukemia Patients

Mingjia Li, MD, Aziz Nazha, MD, Paul Elson, Sean Hobson, MA, Mikkael A. Sekeres, MD MS, Matt E. Kalaycio, MD, Ronald M. Sobecks, MD, Aaron Gerds, MDMS, Betty K. Hamilton, MD, Sudipto Mukherjee, MD MPH, Hetty E. Carraway, MD, Anjali S. Advani, MD

Blood (2014) 124 (21): 5252.

https://doi.org/10.1182/blood.V124.21.5252.5252

Published: 2014

Journal Articles

Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial

Blood (2014) 124 (21): 978.

https://doi.org/10.1182/blood.V124.21.978.978

Published: 2014

Journal Articles

Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1 st -Line Therapy

Christopher R. Cogle, MD, Sudipto Mukherjee, MD MPH, Tanya GK Bentley, PhD, Michael S Broder, MD MSHS, Eunice Chang, PhD, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Scott Megaffin, Rita Percy, Michael E. Petrone, MD MPH, Gordon H Sun, MD MS

Blood (2014) 124 (21): 2627.

https://doi.org/10.1182/blood.V124.21.2627.2627

Published: 2014

Journal Articles

Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1 st -Line Therapy, Discontinuation and the Need of Additional Therapies

Sudipto Mukherjee, MD MPH, Christopher R. Cogle, MD, Tanya GK Bentley, PhD, Michael S Broder, MD MSHS, Eunice Chang, PhD, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Scott Megaffin, Rita Percy, Michael E. Petrone, MD MPH, Gordon H Sun, MD MS

Blood (2014) 124 (21): 2598.

https://doi.org/10.1182/blood.V124.21.2598.2598

Published: 2014

Journal Articles

Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)

Christopher R. Cogle, MD, Sudipto Mukherjee, MD MPH, Moira E. Lawrence, PhD, Thomas J. McKearn, MD PhD, Rita Percy, Michael E. Petrone, MD MPH, Scott Megaffin, Ayanna M Anene, BS, Jesse Ortendahl, MS, Dorothy Romanus, RPh, PhD, Tanya GK Bentley, PhD

Blood (2014) 124 (21): 1928.

https://doi.org/10.1182/blood.V124.21.1928.1928

Published: 2014

Journal Articles

Comparison of Very Low-Dose Decitabine to Standard-Dose Hypomethylating Agents in Myelodysplastic Syndromes (MDS)

Connie Cheng, PharmD, Caitlin Siebenaller, PharmD, Paul Elson, PhD, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Kristin Colaluca, RN, Betty K. Hamilton, MD, Sean Hobson, MA, Matt E. Kalaycio, MD, Jaroslaw P. Maciejewski, MD PhD, Sudipto Mukherjee, MD MPH, Gin Rupp, RN, Cassie Zimmerman, MA, Mikkael A. Sekeres, MD MS, Aaron T. Gerds, MD MS

Blood (2014) 124 (21): 1933.

https://doi.org/10.1182/blood.V124.21.1933.1933

Published: 2014

Journal Articles

Effect of Early Non-Hematologic Treatment Toxicity on Complete Remission (CR) and Time to CR in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy

Surbhi Sidana, MD, Mayur Narkhede, MD, Tomas Radivoyevitch, PhD, Moshe C. Ornstein, MD MA, Cassandra Fincher, Amanda L. Maggiotto, BS, CCRP, Yogen Saunthararajah, MD, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Hetty E. Carraway, MD MBA, Betty K. Hamilton, MD, Matt E. Kalaycio, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD MPH

Blood (2014) 124 (21): 2279.

https://doi.org/10.1182/blood.V124.21.2279.2279

Published: 2014

Journal Articles

A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS)

Aziz Nazha, MD, David J. Seastone, DO, PhD, Tomas Radivoyevitch, PhD, Aaron T. Gerds, MD MS, Sudipto Mukherjee, MD MPH, Hetty E. Carraway, MD, Anjali S. Advani, MD, Matt E. Kalaycio, MD, Gina Rupp, Kristin Colaluka, Sean Hobson, MA, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2014) 124 (21): 168.

https://doi.org/10.1182/blood.V124.21.168.168

Published: 2014

Journal Articles

DDX41 Is a Tumor Suppressor Gene Associated with Inherited and Acquired Mutations

Blood (2014) 124 (21): 125.

https://doi.org/10.1182/blood.V124.21.125.125

Published: 2014

NARROW

Distinct Pattern of Genomic Changes Associated with Hypoplastic Compared to Hyper/Normoblastic Myelodysplastic Syndromes (MDS)

Molecular Predictors of Response in Patients with Myeloid Neoplasms Treated with Lenalidomide

Differences in Genomic Patterns and Clinical Outcomes Between African-American and White Patients with Myelodysplastic Syndromes (MDS)

Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia

Estimating Therapy-Related Myeloid Neoplasm Risks in the US

Time to Complete Remission As a Function of Kinetics of White Blood Cell Elimination and Recovery in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy

A Prognostic Scoring System for Newly Diagnosed Adult Acute Lymphocytic Leukemia Patients

Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial

Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1 st -Line Therapy

Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1 st -Line Therapy, Discontinuation and the Need of Additional Therapies

Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)

Comparison of Very Low-Dose Decitabine to Standard-Dose Hypomethylating Agents in Myelodysplastic Syndromes (MDS)

Effect of Early Non-Hematologic Treatment Toxicity on Complete Remission (CR) and Time to CR in Acute Myeloid Leukemia Patients Undergoing Remission Induction Chemotherapy

A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS)

DDX41 Is a Tumor Suppressor Gene Associated with Inherited and Acquired Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only